PATH | VRL
Menu

Effect of a Serogroup A Meningococcal Conjugate Vaccine (PsA—TT) on Serogroup A Meningococcal Meningitis and Carriage in Chad: A Community Study

A serogroup A meningococcal polysaccharide—tetanus toxoid conjugate vaccine (PsA—TT, MenAfriVac) was licensed in India in 2009, and prequalified by the World Health Organization in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African Meningitis Belt. The authors of this article, published in The Lancet, studied the effect of PsA—TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic. Results showed that PsA—TT was highly effective at prevention of serogroup A invasive meningococcal disease and carriage in Chad, though how long this protection persists remains to be established.

Author: Daugla DM, Gami JP, Gamougam K, et al.

Published: 2013

» Visit web page (English)

(Located at www.thelancet.com)

Citation: Daugla DM, Gami JP, Gamougam K, et al. Effect of a Serogroup A Meningococcal Conjugate Vaccine (PsA—TT) on Serogroup A Meningococcal Meningitis and Carriage in Chad: A Community Study. The Lancet. 2013. Early online publication.

Resource types: Peer-reviewed journal

Diseases/vaccines: Meningococcus

Topics: Disease burden and surveillance, Disease/vaccine specific information

Regions: Africa